Skip to main content
Fig. 1 | EJNMMI Research

Fig. 1

From: Radioimmunotherapy study of 131I-labeled Atezolizumab in preclinical models of colorectal cancer

Fig. 1

Analysis of PD-L1 expression and cytotoxicity of 131I-Atezolizumab on colorectal cancer cells. a Flow cytometry analysis of PD-L1 expression in different colorectal cancer cells (RKO, DLD-1, HCT8 and Caco-2). b FlowJo was used to conduct a quantitative analysis of mean fluorescence intensity. c PD-L1 (50 kDa) expression in cancer cells was analyzed using a western blot with GAPDH (36 kDa) serving as the internal control. d Cell binding assay of 131I-Atezolizumab. e The immunoreactive fraction of 131I-Atezolizumab and RKO cells. f Cytotoxicity of 131I-Atezolizumab

Back to article page